GLP-1 Drugs Show Mixed Effects on Brain Health: Neuroprotection Signals but Dementia Risk Questions
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
New research presents a mixed picture of how GLP-1 receptor agonists affect brain health, with one study suggesting an increased risk of cognitive impairment after long-term use while a separate review finds promising signals that the drugs could slow neurodegeneration.
Researchers from Johns Hopkins University School of Medicine and New York Medical College in Valhalla reported that Type 2 diabetic adults taking GLP-1 medications face an increased risk of developing cognitive impairment after a decade of use, compared with those who do not take the drugs. The findings were presented at the American Academy of Neurology annual meeting in Chicago. However, the researchers cautioned that the increased risks may be linked to GLP-1 patients living longer, particularly women, and said additional clinical trials are needed to better understand any link between GLP-1s and dementia.
In contrast, a recent review published in the Journal of Clinical Investigation examined the biological mechanisms and clinical potential of GLP-1 receptor agonists as disease-modifying therapies for neurodegenerative diseases. The authors found that GLP-1RAs activate pathways that overlap with insulin signaling, and by restoring metabolic balance, they may interrupt the cycle linking insulin resistance and neurodegeneration. Some researchers have described these agents as partial pharmacological mimics of exercise-related metabolic signaling.
Preclinical studies have shown reduced toxic protein burden and preserved neuronal integrity with GLP-1RAs, though definitive disease-modifying effects in humans remain unproven. Imaging studies using fluorodeoxyglucose positron emission tomography suggest that some treated patients maintain cerebral glucose metabolism longer. However, whether these effects reflect direct brain penetration or systemic metabolic changes remains uncertain, and consistent cognitive benefits have not been established.
Observational studies have reported a lower incidence of dementia among GLP-1 users, and a phase II trial of lixisenatide suggested modest slowing of motor progression in Parkinson's disease. By 2040, neurodegenerative diseases are projected to become the second leading cause of death worldwide, based on epidemiological modeling projections. Rates of Alzheimer's disease, Parkinson's disease, and related conditions have increased in the aging global population, yet only a limited number of pharmacological treatments can modify disease course.
The GLP-1 drug class includes Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity, and Rybelsus. Novo Nordisk manufactures Ozempic and Wegovy (both containing semaglutide), while Eli Lilly manufactures Mounjaro and Zepbound. Both companies are rolling out tablet and pill versions of the usually injectable medications.